Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs

Acta Orthopaedica

Volumn 76, Issue 5, 2005, Pages 614-619

  Konttinen, Yrjö T ^a   Seitsalo, Seppo ^b   Lehto, Matti ^c   Santavirta, Seppo ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^c Hospital for Joint Replacement   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOTRANSFERASE; ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; AUROTHIOMALATE; AZATHIOPRINE; CREATINE KINASE; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA ANTIBODY; ETANERCEPT; GLUCOCORTICOID; HYDROXYCHLOROQUINE; IMATINIB; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 6 BLOCKING AGENT; ISONIAZID; LEFLUNOMIDE; LIVE VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PYRIDOXINE; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEM CELL FACTOR RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTHRALGIA; BREATHING DISORDER; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG INDICATION; ECZEMA; EDEMA; FLU LIKE SYNDROME; HEADACHE; HUMAN; HYPEREMIA; HYPOTENSION; INFECTION COMPLICATION; INJECTION SITE REACTION; JOINT EFFUSION; MYALGIA; NAUSEA; NONHUMAN; PRURITUS; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SERUM SICKNESS; SPONDYLOARTHROPATHY; SYNOVITIS; URTICARIA; VOMITING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; OPPORTUNISTIC INFECTIONS; PRACTICE GUIDELINES; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS;

EID: 27644520811     PISSN: 17453674     EISSN: 17453682     Source Type: Journal    
DOI: 10.1080/17453670510041673     Document Type: Review

References (12)

1. Cohen S B, Moreland L W, Cush J J, Greenwald M W, Block S, Shergy W J, Hanrahan P S, Kraishi M M, Patel A, Sun G, Bear M B. 990145 Study Group. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis. 2004; 63: 1062-8.
2. Doran M F, Crowson C S, Pond G R, O'Fallon W M, Gabriel S E. Frequency of infection in patient with rheumatoid arthritis compared with controls. Arthritis Rheum 2002; 46: 2287-93.
3. Edwards J C, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close D R, Stevens R M, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004; 350: 2572-81.
4. Keane J, Gershon S, Wise R P, Mirabile-Levens E, Kasznica J, Schwieterman W D, Siegel J N, Braun M M. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med 2001; 345: 1098-104.
5. Keystone E C, Kavanaugh A F, Sharp J T, Tannenbaum H, Hua Y, Teoh L S, Fischkoff S A, Chartash E K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-11.
6. Lipsky P E, van der Heijde D M, St Clair E W, Furst D E, Breedveld F C, Kalden J R, Smolen J S, Weisman M, Emery P, Feldmann M, Harriman G R, Maini R N. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. N Engl J Med. 2000; 343: 1594-602.
7. Maini R, St Clair E W, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999; 354: 1932-9.
8. Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann R M, Weaver A L, Ettlinger R E, Cohen S, Koopman W J, Mohler K, Widmer M B, Blosch C M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997; 337: 141-7.
9. Moreland L W, Schiff M H, Baumgartner S W, Tindall E A, Fleischmann R M, Bulpitt K J, Weaver A L, Keystone E C, Furst D E, Mease P J, Ruderman E M, Horwitz D A, Arkfeld D G, Garrison L, Burge D J, Blosch C M, Lange M L, McDonnell N D, Weinblatt M E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478-86.
10. Nordström D C, Konttinen L, Korpela M, Tiippana-Kinnunen T, Eklund K, Forsberg S, Ilva K, Kaipainen-Seppänen O, Malmi T, Ylä-Kerttula T, Honkanen V, on behalf of the ROB-FIN study group: Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finish experience. Rheumatol Int, in press.
11. Weinblatt M E, Kremer J M, Bankhurst A D, Bulpitt K J, Fleischmann R M, Fox R I, Jackson C G, Lange M, Burge D J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340: 253-9.
12. van de Putte L B, Atkins C, Malaise M, Sany J, Russell A S, van Riel P L, Settas L, Bijlsma J W, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004; 63: 508-16.